22th Annual Kasha Award Seminar Speaker

Rumana Rashid Ph.D.
Lead Scientist, Protein Sciences, Xencor, Inc.

Bispecific Antibodies: A Modular Approach to Build Novel Cancer Immunotherapies

Xencor has developed a new platform for long-lived and easy-to-manufacture bispecific antibodies.
We have applied it to rapidly produce CD3 bispecific antibodies targeting CD123 for AML (Acute Myelogenous Leukemia),
CD20 for B cell malignancies, and CD38 for multiple myeloma. Each antibody is shown to be potently active in in-vivo studies,
and GMP manufacturing is straightforward with yields over 2 g/L.